PV 705

Drug Profile

PV 705

Latest Information Update: 21 Aug 2003

Price : $50

At a glance

  • Originator International Diabetes Institute
  • Developer GroPep; International Diabetes Institute
  • Class
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 28 Mar 2002 Discontinued - Phase-II for Diabetic neuropathies in Australia (Topical)
  • 18 Jul 2001 Phase-II clinical trials for Diabetic neuropathies in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top